YTHDC2 and cancer: Considering that the SLC7A11/GPX4 axis has demonstrated therapeutic value in multiple disease models, including stroke, cancer, and sepsis, our study provides compelling evidence that targeting post-transcriptional regulators such as the METTL3/lncRNA-AU020206/YTHDC2 molecular network may yield novel and effective strategies for the prevention and treatment of ischemic brain injury.